BioTuesdays

HCW starts Aravive at buy; PT $18

H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9.

The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to specifically inhibit the activation of the only receptor for GAS6, AXL, a key regulator of tumorigenesis and resistance to therapy. 

“We believe the chosen target and strategy could make of AVB-500 a compelling asset for the treatment of various tumor indications and a valuable ally in the context of combinatory therapies in multiple lines of treatment,” writes analyst Joseph Pantginis. 

The company’s primary focus is on the clinical development of AVB-500 for the treatment of patients with platinum-resistant ovarian cancer. An ongoing Phase 1b/2 study recently showed compelling safety and efficacy data while demonstrating a strong correlation between drug exposure and anti-tumor activity of AVB-500, “which we think opens the possibility of exploring an accelerated path forward with the FDA,” he added. 

“With important upcoming near-term catalysts and an underlying strategy de-risked by solid scientific evidence, we believe Aravive represents and intriguing opportunity at this early stage,” Mr. Pantginis said.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.